Post-transplant Hepatitis C Approved for Marketing Phase Trials for Ribavirin (DB00811)

IndicationStatusPhase
DBCOND0061591 (Post-transplant Hepatitis C)Approved for MarketingNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01779518Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C